{"title":"耐多药结核病和糖尿病合并症的患病率和治疗效果","authors":"L. Todoriko, I. Semianiv","doi":"10.31215/2306-4927-2022-30-2-42-47","DOIUrl":null,"url":null,"abstract":"The aim of the study is a comprehensive retrospective assessment of the prevalence, features, course of treatment of multidrug-resistant tuberculosis (MDR-TB) and diabetes mellitus (DM) comorbidity. Materials and methods. The study is based on an analysis of statistical data obtained from a retrospective study of 762 case histories and cases of MDR-TB in the register of tuberculosis patients from different regions of Ukraine and Grodno region of the Republic of Belarus for 2016-2020 years. In all patients MDR-TB was diagnosed retrospectively. The patients were allocated in two groups: group 1 — 88 patients with MDR-TB and DM comorbidity; group 2 — 674 patients with MDR-TB only. Results. In both study groups the recurrence of TB prevailed — 49 cases (55.7%) vs newly diagnosed TB 39 cases (44.3%) in the group 1 and 363 cases (53.9%) vs 311 (46.1%), respectively, in the group 2 (p <0.05). The rate of successful treatment in group 2 was higher than in group 1 (64.7% vs. 61.4%; (p <0.05)). However, more significant probable difference was characterized the cure rate: 27.3% in group 1 vs 40.3% in group 2 (almost 2 times; p <0.05). The rate of ineffective treatment, which in patients with comorbidity was 27.3% (almost every third patient) vs 17.6% in group 2 was also important for scientists and practitioners. Conclusions. There is a clear tendency to higher rate of comorbidities/ chemoresistance and relapses of TB in patients with comorbid DM. Pulmonary TB developed significantly more often in middle-aged patients with type 2 DM (moderate to severe, subcompensated and complicated course). Key words: resistant tuberculosis, diabetes mellitus, carbohydrate metabolism, treatment.","PeriodicalId":328937,"journal":{"name":"Ukrainian Pulmonology Journal","volume":"45 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PREVALENCE AND EFFECTIVENESS OF TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS AND DIABETES MELLITUS COMORBIDITY\",\"authors\":\"L. Todoriko, I. Semianiv\",\"doi\":\"10.31215/2306-4927-2022-30-2-42-47\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of the study is a comprehensive retrospective assessment of the prevalence, features, course of treatment of multidrug-resistant tuberculosis (MDR-TB) and diabetes mellitus (DM) comorbidity. Materials and methods. The study is based on an analysis of statistical data obtained from a retrospective study of 762 case histories and cases of MDR-TB in the register of tuberculosis patients from different regions of Ukraine and Grodno region of the Republic of Belarus for 2016-2020 years. In all patients MDR-TB was diagnosed retrospectively. The patients were allocated in two groups: group 1 — 88 patients with MDR-TB and DM comorbidity; group 2 — 674 patients with MDR-TB only. Results. In both study groups the recurrence of TB prevailed — 49 cases (55.7%) vs newly diagnosed TB 39 cases (44.3%) in the group 1 and 363 cases (53.9%) vs 311 (46.1%), respectively, in the group 2 (p <0.05). The rate of successful treatment in group 2 was higher than in group 1 (64.7% vs. 61.4%; (p <0.05)). However, more significant probable difference was characterized the cure rate: 27.3% in group 1 vs 40.3% in group 2 (almost 2 times; p <0.05). The rate of ineffective treatment, which in patients with comorbidity was 27.3% (almost every third patient) vs 17.6% in group 2 was also important for scientists and practitioners. Conclusions. There is a clear tendency to higher rate of comorbidities/ chemoresistance and relapses of TB in patients with comorbid DM. Pulmonary TB developed significantly more often in middle-aged patients with type 2 DM (moderate to severe, subcompensated and complicated course). Key words: resistant tuberculosis, diabetes mellitus, carbohydrate metabolism, treatment.\",\"PeriodicalId\":328937,\"journal\":{\"name\":\"Ukrainian Pulmonology Journal\",\"volume\":\"45 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ukrainian Pulmonology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31215/2306-4927-2022-30-2-42-47\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ukrainian Pulmonology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31215/2306-4927-2022-30-2-42-47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
该研究的目的是对耐多药结核病(MDR-TB)和糖尿病(DM)合并症的患病率、特征和治疗过程进行全面的回顾性评估。材料和方法。该研究基于对2016-2020年乌克兰不同地区和白俄罗斯共和国格罗德诺地区结核病患者登记册中762例病例史和耐多药结核病病例的回顾性研究所获得的统计数据的分析。对所有患者进行回顾性诊断。患者被分为两组:1组- 88例耐多药结核病合并糖尿病患者;第2组- 674例耐多药结核病患者。结果。在两个研究组中,结核病复发率普遍存在——1组49例(55.7%)vs新诊断结核病39例(44.3%),2组分别为363例(53.9%)vs 311例(46.1%)(p <0.05)。2组治疗成功率高于1组(64.7% vs. 61.4%;(p < 0.05)。然而,更显著的可能差异是治愈率:1组27.3% vs 2组40.3%(几乎是2倍;p < 0.05)。对于科学家和从业者来说,治疗无效的比例也很重要,在合并症患者中,治疗无效的比例为27.3%(几乎每三名患者中就有一例),而在第二组中,治疗无效的比例为17.6%。结论。合并糖尿病患者的结核病合并症/化疗耐药率和复发率明显增高。中年2型糖尿病患者(中重度、亚代偿和复杂病程)发生肺结核的几率明显更高。关键词:耐药结核,糖尿病,碳水化合物代谢,治疗。
PREVALENCE AND EFFECTIVENESS OF TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS AND DIABETES MELLITUS COMORBIDITY
The aim of the study is a comprehensive retrospective assessment of the prevalence, features, course of treatment of multidrug-resistant tuberculosis (MDR-TB) and diabetes mellitus (DM) comorbidity. Materials and methods. The study is based on an analysis of statistical data obtained from a retrospective study of 762 case histories and cases of MDR-TB in the register of tuberculosis patients from different regions of Ukraine and Grodno region of the Republic of Belarus for 2016-2020 years. In all patients MDR-TB was diagnosed retrospectively. The patients were allocated in two groups: group 1 — 88 patients with MDR-TB and DM comorbidity; group 2 — 674 patients with MDR-TB only. Results. In both study groups the recurrence of TB prevailed — 49 cases (55.7%) vs newly diagnosed TB 39 cases (44.3%) in the group 1 and 363 cases (53.9%) vs 311 (46.1%), respectively, in the group 2 (p <0.05). The rate of successful treatment in group 2 was higher than in group 1 (64.7% vs. 61.4%; (p <0.05)). However, more significant probable difference was characterized the cure rate: 27.3% in group 1 vs 40.3% in group 2 (almost 2 times; p <0.05). The rate of ineffective treatment, which in patients with comorbidity was 27.3% (almost every third patient) vs 17.6% in group 2 was also important for scientists and practitioners. Conclusions. There is a clear tendency to higher rate of comorbidities/ chemoresistance and relapses of TB in patients with comorbid DM. Pulmonary TB developed significantly more often in middle-aged patients with type 2 DM (moderate to severe, subcompensated and complicated course). Key words: resistant tuberculosis, diabetes mellitus, carbohydrate metabolism, treatment.